ArticleTherapeutic advances in neurological disorders2012
Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany.
Article in Therapeutic advances in neurological disorders, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 38 citations in OpenAlex.
- Condensate State as Determinant of Amyloid Pathology in Neurodegeneration.Biomolecules · 2026Review
- Review
- Article
- Does physical exercise improve or deteriorate treatment of multiple sclerosis with mitoxantrone? Experimental autoimmune encephalomyelitis study in rats.BMC neuroscience · 2022Article
- Identification of geraldol as an inhibitor of aquaporin‑4 binding by NMO‑IgG.Molecular medicine reports · 2020Article
- Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 1.International journal of physiology, pathophysiology and pharmacology · 2019Review
- Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis.Frontiers in neurology · 2018Review
- Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: a cohort study.BMC neurology · 2017Article
- Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.Deutsches Arzteblatt international · 2016Review
- Malignancies after mitoxantrone for multiple sclerosis: A retrospective cohort study.Neurology · 2016Observational
- [Current immunotherapy of multiple sclerosis].Der Nervenarzt · 2015Article
- The transition from first-line to second-line therapy in multiple sclerosis.Current treatment options in neurology · 2015Article
- Ultrahigh field MRI in clinical neuroimmunology: a potential contribution to improved diagnostics and personalised disease management.The EPMA journal · 2015Review
- Risk evaluation and monitoring in multiple sclerosis therapeutics.Multiple sclerosis (Houndmills, Basingstoke, England) · 2014Review
- Neuromyelitis optica: clinical features, immunopathogenesis and treatment.Clinical and experimental immunology · 2014Review
- Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system.Clinical and experimental immunology · 2014Review
- Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).Journal of neurology · 2014Review
- Article
- Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?The EPMA journal · 2013Article
Corrections and comments
- Erratum issuedPaul, Friedmann [corrected to Friedemann, Paul]
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe incidence of therapy-related acute leukaemia (TRAL) in mitoxantrone treatment in multiple sclerosis (MS) is controversially discussed. METHODS AND
resultsIn a retrospective meta-analysis from six centres, we observed six cases of acute myeloid leukaemia (AML) (incidence 0.41% for patients with mean follow up after end of treatment of 3.6 years, n = 1.156; incidence 0.25% for all patients, n = 2.261). Potential influencing factors such as myelotoxic or glucocorticosteroid pretreatment/cotreatment were present in all but one case of TRAL. Between 1990 and 2010, 11 cases of TRAL were reported to the Drug Commission of the German Medical Association (estimated risk of 0.09-0.13%).
conclusionsRegional differences in reported TRAL incidence may point to confounding cofactors such as administration protocols and cotreatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.